• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Bausch + Lomb Launches ASANA™ Gas Permeable Lenses in the United States

    9/8/25 7:00:00 AM ET
    $BLCO
    Ophthalmic Goods
    Health Care
    Get the next $BLCO alert in real time by email
    • ASANA offers a comprehensive, customizable gas permeable portfolio including spherical, aspheric, toric, multifocal, reverse geometry and keratoconic lenses
    • Designed for durability, ASANA lenses maintain shape throughout the day, resist protein buildup, and provide enhanced visual acuity, particularly for patients with complex vision challenges such as astigmatism, keratoconus and post-surgical conditions
    • Eye care professionals using ASANA can benefit from Bausch + Lomb consultant support for lens fittings, fast manufacturing and shipping and a 120-day EZ-Exchange™ Warranty Program offering unlimited lens remakes*

    Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of ASANA gas permeable (GP) lenses. ASANA offers eye care professionals a versatile, all-in-one comprehensive GP portfolio, featuring spherical, aspheric, toric, multifocal, multifocal toric, reverse geometry and keratoconic contact lenses.

    "Many still prefer rigid gas permeable contact lenses for clear, comfortable and consistent vision," said Yang Yang, president, Global Vision Care, Bausch + Lomb. "ASANA offers eye care professionals a catalog of customizable GP lenses designed to fit each patient's unique corneal curves, ensuring a fantastic fit and sharp vision. These GP lenses also complete our custom Specialty Vision Products lens portfolio, offering a comprehensive range of options – from scleral to custom soft, ortho-K and now custom GP lenses."

    ASANA GP lenses are designed to maintain their shape throughout the day, delivering excellent visual acuity. Their rigid material resists protein and fatty deposits, helping to maintain clarity and comfort. Highly durable, they offer strong resistance to breaking and chipping, which can make them a cost-effective option due to less frequent replacement.1-3 For patients with high corneal astigmatism, severe refractive errors, keratoconus, corneal irregularities or post-surgical vision correction needs, gas permeable lenses provide enhanced visual precision to address these more complex vision challenges.1,2

    "Rigid gas permeable corneal contact lenses are an excellent option for certain patients, and having access to consultants to assist with fittings is a critical component of success," said James R. Hoffman, OD, FAAO, Orange Park Eye Center, Orange Park, Florida. "With ASANA, eye care professionals get both, along with fast manufacturing and shipping times, a generous warranty period and an extensive range of lens designs such as spherical, toric, multifocal and more. It's an excellent option, particularly for busy practices."

    ASANA GP lenses are custom made exclusively with Boston® materials, and through the EZ-Exchange Warranty Program, unlimited lens remakes are available for 120 days.* For more information on ASANA GP lens portfolio, visit https://www.bauschsvp.com/lenses/asana/.

    Important Safety Information for Gas Permeable and Customized Soft Contact Lenses

    WARNINGS:

    Patients should be advised of the following warnings pertaining to contact lens wear:

    • Problems with contact lenses and lens care products could result in serious injury to the eye. It is essential that patients follow their eye care practitioner's directions and all labeling instructions for proper use of lenses and lens care products, including the lens case. Eye problems, including corneal ulcers, can develop rapidly and lead to loss of vision.
    • Daily wear lenses are not indicated for overnight wear, and patients should be instructed not to wear lenses while sleeping. Clinical studies have shown that the risk of serious adverse reactions is increased when daily wear lenses are worn overnight.
    • Studies have shown that contact lens wearers who are smokers have a higher incidence of adverse reactions than nonsmokers.
    • If a patient experiences eye discomfort, excessive tearing, vision changes or redness of the eye, the patient should be instructed to immediately remove lenses and promptly contact his or her eyecare practitioner.

    CONTRAINDICATIONS:

    Do not use when any of the following conditions exist:

    • Acute or subacute inflammation or infection of the anterior chamber of the eye.
    • Any eye disease, injury or abnormality, other than keratoconus and PMD that affects the cornea, conjunctiva or eyelids
    • Severe insufficiency of lacrimal secretion (dry eye)
    • Corneal hypoesthesia (reduced sensitivity), if not aphakic
    • Any systemic disease that may affect the eye or be exaggerated by wearing contact lenses
    • Allergic reactions of ocular surfaces or adnexa that may be induced or exaggerated by wearing contact lenses or using contact lens solutions
    • Allergy to any ingredient in a solution, which is to be used to care for contact lenses
    • Any active corneal infection (bacterial, fungal or viral)
    • Red or irritated eyes

    ADVERSE EFFECTS:

    The following problems may occur with the use of contact lenses:

    • Eyes stinging, burning, itching, irritation or other eye pain
    • Comfort is less than when the lens was first placed on the eye
    • Feeling of something in the eye such as a foreign body or scratched area
    • Excessive watering (tearing) of the eye
    • Unusual eye secretions
    • Redness of the eyes
    • Reduced sharpness of vision (poor visual acuity)
    • Blurred vision, rainbows or halos around objects
    • Sensitivity to light (photophobia)
    • Dry eyes 

    About Bausch + Lomb

    Our mission is simple – we help people see better to live better, all over the world. For nearly two centuries we've evolved with the changing needs of patients and customers, and our commitment to innovation and improving the standard of care in eye health has never been stronger. From contact lenses to prescription products, over-the-counter options, surgical devices and more, we're turning bold ideas into better outcomes through passion, perseverance and purpose. Learn more at www.bausch.com and connect with us on Facebook, Instagram, LinkedIn, X and YouTube.

    *See bauschsvp.com/policies for details.

    References

    1. Lazarus R. Optometrists Network. Guide to hard contact lenses. Accessed July 20, 2025. optometrists.org/general-practice-optometry/optical/guide-to-contact-lenses/guide-to-hard-contact-lenses/.
    2. Wolffsohn JS, Dumbleton K, Huntjens B, et al. CLEAR - Evidence-based contact lens practice. Cont Lens Anterior Eye. 2021;44(2):368-397.
    3. Heiting G. All About Vision. Gas permeable contact lenses (RGP or GP contacts). Accessed July 20, 2025. allaboutvision.com/eyewear/contact-lenses/types/hard-contact-lenses/.

    ©2025 Bausch + Lomb.

    MTB.0473.USA.25

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250908684391/en/

    Media Contact:

    Kristy Marks

    [email protected]

    (908) 927-0683

    Get the next $BLCO alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BLCO

    DatePrice TargetRatingAnalyst
    5/2/2025$20.00 → $15.00Buy
    H.C. Wainwright
    3/28/2025$24.00 → $15.00Overweight → Equal Weight
    Wells Fargo
    12/11/2024$24.00 → $22.00Buy → Neutral
    Citigroup
    12/2/2024$19.00Overweight → Equal-Weight
    Morgan Stanley
    10/15/2024$19.00 → $25.00In-line → Outperform
    Evercore ISI
    7/10/2024$19.00Outperform
    Raymond James
    5/6/2024$16.00 → $18.00Equal-Weight → Overweight
    Morgan Stanley
    1/4/2024$19.00 → $17.00Outperform → In-line
    Evercore ISI
    More analyst ratings

    $BLCO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Bausch + Lomb Announces Publication of enVista Envy™ Full Range of Vision Intraocular Lens Pivotal U.S. Clinical Trial

    enVista Envy full range of vision intraocular lens (IOL) met all primary efficacy and safety endpoints in multicenter study Results show that enVista Envy IOLs deliver excellent visual performance, good contrast sensitivity and a favorable dysphotopsia profile Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that the American Journal of Ophthalmology has published results of the pivotal U.S. clinical trial of the enVista Envy novel full visual range intraocular lens. The study compared visual, refractive and patient-reported outcomes following implantation of enVista Envy and the enVi

    9/11/25 7:00:00 AM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    Bausch + Lomb Announces Publication of Data From a Prospective Study Evaluating the Efficacy of XIIDRA® in Alleviating Discomfort in Symptomatic Contact Lens Wearers

    XIIDRA significantly improved end-of-day eye dryness and discomfort and delivered longer comfortable contact lens wear time in as little as two weeks Continued use further improved discomfort Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced Clinical Ophthalmology has published results from an investigator-initiated study which evaluated the effectiveness of XIIDRA (lifitegrast ophthalmic solution) 5% in alleviating end-of-day (EOD) eye dryness and discomfort in symptomatic contact lens (CL) wearers.* XIIDRA is a prescription eye drop used to treat the signs and symptoms of dry eye dis

    9/9/25 7:00:00 AM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    Bausch + Lomb Launches ASANA™ Gas Permeable Lenses in the United States

    ASANA offers a comprehensive, customizable gas permeable portfolio including spherical, aspheric, toric, multifocal, reverse geometry and keratoconic lenses Designed for durability, ASANA lenses maintain shape throughout the day, resist protein buildup, and provide enhanced visual acuity, particularly for patients with complex vision challenges such as astigmatism, keratoconus and post-surgical conditions Eye care professionals using ASANA can benefit from Bausch + Lomb consultant support for lens fittings, fast manufacturing and shipping and a 120-day EZ-Exchange™ Warranty Program offering unlimited lens remakes* Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye hea

    9/8/25 7:00:00 AM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    $BLCO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright reiterated coverage on Bausch + Lomb with a new price target

    H.C. Wainwright reiterated coverage of Bausch + Lomb with a rating of Buy and set a new price target of $15.00 from $20.00 previously

    5/2/25 7:51:06 AM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    Bausch + Lomb downgraded by Wells Fargo with a new price target

    Wells Fargo downgraded Bausch + Lomb from Overweight to Equal Weight and set a new price target of $15.00 from $24.00 previously

    3/28/25 8:14:16 AM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    Bausch + Lomb downgraded by Citigroup with a new price target

    Citigroup downgraded Bausch + Lomb from Buy to Neutral and set a new price target of $22.00 from $24.00 previously

    12/11/24 7:25:38 AM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    $BLCO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP, Controller and CAO Munsch Frederick was granted 7,529 shares, increasing direct ownership by 11% to 77,733 units (SEC Form 4)

    4 - Bausch & Lomb Corp (0001860742) (Issuer)

    8/7/25 4:48:43 PM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    EVP and CFO Eldessouky Sam was granted 42,517 shares, increasing direct ownership by 15% to 320,816 units (SEC Form 4)

    4 - Bausch & Lomb Corp (0001860742) (Issuer)

    8/7/25 4:46:53 PM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    President, Surgical Bonnefoy Luc was granted 6,146 shares, increasing direct ownership by 9% to 77,362 units (SEC Form 4)

    4 - Bausch & Lomb Corp (0001860742) (Issuer)

    8/7/25 4:42:26 PM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    $BLCO
    SEC Filings

    View All

    Bausch + Lomb Corporation filed SEC Form 8-K: Termination of a Material Definitive Agreement, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Bausch & Lomb Corp (0001860742) (Filer)

    8/18/25 5:06:46 PM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    SEC Form 10-Q filed by Bausch + Lomb Corporation

    10-Q - Bausch & Lomb Corp (0001860742) (Filer)

    7/30/25 5:17:52 PM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    Bausch + Lomb Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Bausch & Lomb Corp (0001860742) (Filer)

    7/30/25 7:00:37 AM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    $BLCO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO and Chairman of the Board Saunders Brent L bought $248,072 worth of shares (22,000 units at $11.28) and was granted 22,000 shares, increasing direct ownership by 6% to 741,156 units (SEC Form 4)

    4 - Bausch & Lomb Corp (0001860742) (Issuer)

    5/27/25 8:16:24 AM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    Director Von Eschenbach Andrew C. bought $19,925 worth of shares (1,695 units at $11.76), increasing direct ownership by 4% to 41,748 units (SEC Form 4)

    4 - Bausch & Lomb Corp (0001860742) (Issuer)

    5/6/25 4:30:10 PM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    CEO and Chairman of the Board Saunders Brent L bought $505,067 worth of shares (32,250 units at $15.66) and was granted 32,250 shares, increasing direct ownership by 11% to 627,419 units (SEC Form 4)

    4 - Bausch & Lomb Corp (0001860742) (Issuer)

    8/7/24 5:29:48 PM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    $BLCO
    Leadership Updates

    Live Leadership Updates

    View All

    Bausch + Lomb Announces 2025 Annual Meeting of Shareholders Results

    Bausch + Lomb Corporation (NYSE/TSX:BLCO) ("Bausch + Lomb" or the "Company"), a leading global eye health company dedicated to helping people see better to live better, today announced the election of the 10 directors nominated at its 2025 Annual Meeting of Shareholders (the "Annual Meeting") held on May 21, 2025. Detailed results of the vote follow: Name For   Against   Broker Non-Votes Nathalie Bernier   337,617,248   1,924,336   8,383,437 Gary Hu   337,591,706   1,949,878   8,383,437 Brett Icahn   337,474,287   2,067,297   8,383,437 Sarah B. Kavanagh   337,602,211   1,939,373  

    5/21/25 4:30:00 PM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    Bausch + Lomb Announces Appointment of Karen L. Ling to Board of Directors

    Richard De Schutter to Retire from Board Following 2024 Annual Meeting Bausch + Lomb Corporation (TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Karen L. Ling has been appointed to its Board of Directors (the "Board"), effective immediately. Current director Richard De Schutter will retire from the Board effective as of the company's 2024 Annual Meeting of Shareholders (the "Annual Meeting"). With Ms. Ling's appointment, the Board has been temporarily expanded to 11 members and is expected to revert to 10 directors following the Annual Meeting. "Since my return to the company, Richard has been a trusted advisor,

    2/28/24 8:00:00 AM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    Emergent BioSolutions Appoints Industry Leader Joseph C. Papa as New President and CEO

    Papa will lead Emergent into a new era of focusing on protecting public health, returning to growth and paying down the company's debt GAITHERSBURG, Md., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS), a global company providing solutions that address public health threats and delivering life-extending products to market, today announced that its Board of Directors has appointed Joseph C. Papa as president and CEO, effective February 21, 2024. Mr. Papa succeeds Haywood Miller, who will step down from his role as interim CEO, effective February 21, 2024. "Following a thorough search process, we are pleased to appoint Joe Papa as president and CEO of Emergent," sai

    2/21/24 7:00:00 AM ET
    $BLCO
    $EBS
    Ophthalmic Goods
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $BLCO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Bausch + Lomb Corporation

    SC 13G - Bausch & Lomb Corp (0001860742) (Subject)

    2/14/23 5:14:30 PM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    $BLCO
    Financials

    Live finance-specific insights

    View All

    Bausch + Lomb Announces Second-Quarter 2025 Results

    Revenue of $1.278 Billion GAAP Net Loss Attributable to Bausch + Lomb Corporation of $62 Million Adjusted EBITDA (non-GAAP)1 of $191 Million; Adjusted EBITDA Excluding Acquired IPR&D (non-GAAP)1 of $192 Million Revenue Grew 5% as Reported and 3% on a Constant Currency1 Basis Compared to the Second Quarter of 2024, which Absorbs the enVista® Intraocular Lenses Voluntary Recall Raising Full-Year 2025 Guidance to Reflect Solid Business Performance and Impact of Foreign Exchange Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its second-quarter 2025 financial results. "Our con

    7/30/25 6:57:00 AM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    Bausch + Lomb Will Release Second-Quarter 2025 Financial Results on July 30 and Hold Investor Day on Nov. 13

    Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its second-quarter financial results on Wednesday, July 30, 2025. The company will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch + Lomb website prior to the start of the call. Bausch + Lomb will hold an investor day on Thursday, Nov. 13, 2025, where the company will provide a business update and highlight its innovative product pipeline. Additional details will follow closer to the event. Second-Qua

    6/30/25 6:58:00 AM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    Bausch + Lomb Announces First-Quarter 2025 Results

    Revenue of $1.137 Billion GAAP Net Loss Attributable to Bausch + Lomb Corporation of $212 Million Adjusted EBITDA Excluding Acquired IPR&D (non-GAAP)1 of $126 Million Revenue Grew 3% as Reported and 5% on a Constant Currency1 Basis Compared to the First Quarter of 2024 Updating Full-Year 2025 Guidance to Reflect Estimated One-Time Impact of enVista® Intraocular Lenses Voluntary Recall and Impact of Foreign Exchange Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its first-quarter 2025 financial results. "Our core business is performing well, and we remain focused on positioning

    4/30/25 6:57:00 AM ET
    $BLCO
    Ophthalmic Goods
    Health Care